Meeting
2023 ASCO Annual Meeting
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
Authors
Marie N. Becker
Clinical Care Options, Reston, VA
Marie N. Becker , Jame Abraham , Kevin Kalinsky , Laura Spring , Tiffany A. Traina , Timothy A. Quill , Denise A. Yardley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 553)
DOI
10.1200/JCO.2023.41.16_suppl.553
Abstract #
553
Poster Bd #
383
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).
First Author: Miguel Martin
Poster
2023 ASCO Annual Meeting
Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).
First Author: Rima Patel
Poster
2023 ASCO Annual Meeting
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
First Author: Heather L. McArthur
Poster
2021 ASCO Annual Meeting
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
First Author: Frederik Marmé